Skip to main content
Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Fig. 6

A Discontinuations at 1 year ± 2 months of treatment and B primary reasons for discontinuing T2D study medications (Full Analysis Set). AE, adverse event; DPP4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HCP, healthcare professional; SGLT2i, sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840